Who are GEN-004 with Aluminum Hydroxide Adjuvant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CPA, VEC, D-cure, HSPPC-96 or Oncophage, GSK208141 vaccine, Mevac-A vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gen-004-with-aluminum-hydroxide-adjuvant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

GEN-004 with Aluminum Hydroxide Adjuvant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GEN-004 with Aluminum Hydroxide Adjuvant (GEN-004 with Aluminum Hydroxide Adjuvant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic cancer vaccine. Area: Oncology.

phase 2 Therapeutic cancer vaccine Tumor-associated antigens (TAAs) Oncology Biologic Live · refreshed every 30 min

Target snapshot

GEN-004 with Aluminum Hydroxide Adjuvant (GEN-004 with Aluminum Hydroxide Adjuvant) — Genocea Biosciences, Inc.. GEN-004 is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack tumor-associated antigens expressed on cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GEN-004 with Aluminum Hydroxide Adjuvant TARGET	GEN-004 with Aluminum Hydroxide Adjuvant	Genocea Biosciences, Inc.	phase 2	Therapeutic cancer vaccine	Tumor-associated antigens (TAAs)
CPA	CPA	ImmunoVaccine Technologies, Inc. (IMV Inc.)	marketed	Therapeutic cancer vaccine
VEC	VEC	Centre Leon Berard	marketed	Therapeutic cancer vaccine
D-cure	D-cure	KU Leuven	marketed	Therapeutic cancer vaccine
HSPPC-96 or Oncophage	HSPPC-96 or Oncophage	Agenus Inc.	phase 3	Autologous therapeutic cancer vaccine	Tumor-associated antigens presented via Hsp96 complexes
GSK208141 vaccine	GSK208141 vaccine	GlaxoSmithKline	phase 3	Therapeutic cancer vaccine
Mevac-A vaccine	Mevac-A vaccine	Chiang Mai University	phase 3	Therapeutic cancer vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic cancer vaccine class)

GlaxoSmithKline · 2 drugs in this class
Green Cross Corporation · 2 drugs in this class
Chiang Mai University · 1 drug in this class
Chiltern Pesquisa Clinica Ltda · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Galena Biopharma, Inc. · 1 drug in this class
Genocea Biosciences, Inc. · 1 drug in this class
ImmunoVaccine Technologies, Inc. (IMV Inc.) · 1 drug in this class
Istituto Oncologico Veneto IRCCS · 1 drug in this class
KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GEN-004 with Aluminum Hydroxide Adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/gen-004-with-aluminum-hydroxide-adjuvant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab